Tysabri
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Multifocal Leukoencephalopathy
Conditions
Progressive Multifocal Leukoencephalopathy
Trial Timeline
Jun 1, 2017 → Dec 31, 2023
NCT ID
NCT03399981About Tysabri
Tysabri is a pre-clinical stage product being developed by Biogen for Progressive Multifocal Leukoencephalopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT03399981. Target conditions include Progressive Multifocal Leukoencephalopathy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03399981 | Pre-clinical | Completed |
| NCT01071512 | Pre-clinical | Completed |
| NCT00937677 | Pre-clinical | Completed |
| NCT00493298 | Pre-clinical | Completed |
Competing Products
20 competing products in Progressive Multifocal Leukoencephalopathy